GTCB – This settlement indirectly affects GTC because GTC licensed its nuclear-transfer technology from ACTC. Thus, GTC may now owe certain royalties to stART Licensing (the JV of GERN and Exeter) instead of to ACTC, but this shouldn’t make any real difference.
Importantly, this outcome does not affect GTC’s lead, drug, ATryn, because the goat herd for ATryn was created using microinjection rather than nuclear transfer.
News 
Market Data 
Discover 
